Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cullin-associated NEDD8-dissociated protein 1 (CAND1) is an essential regulator of cullin-RING ubiquitin ligases (CRLs), particularly the SCF (Skp1–Cullin1–F-box protein) E3 ligase complexes responsible for targeted protein ubiquitination and proteasomal degradation. CAND1 acts as a "substrate receptor exchange factor," binding to unneddylated cullin scaffolds and displacing the Skp1–F-box protein complex, thereby recycling the cullin scaffold and allowing exchange for new F-box substrate receptors. This process is critical for protein homeostasis, timely cell cycle progression, and cellular adaptation to changing substrate pools. CAND1 dysfunction impairs proteostasis, leading to defective development, increased cell death in certain contexts, and is linked to various human diseases including cancer, metabolic, and cardiovascular disorders. No direct therapeutic drugs target CAND1, but its modulation is being explored for disease treatment and its altered expression is associated with several pathological states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin-associated NEDD8-dissociated protein 1 (CAND1).